logo-loader
Advanced Oncotherapy PLC

Advanced Oncotherapy set to benefit from Large Hadron Collider spin-off

Dr Michael Sinclair, CEO of Advanced Oncotherapy (LON:AVO), tells Proactive Investors his firm is uniquely placed to exploit a strand of particle physics from the Cern Laboratories to combat cancer tumours. Mike says that AVO is working towards producing proton beam therapy machines, at a fraction of the cost of existing machines, using its own patented technology.

Quick facts: Advanced Oncotherapy PLC

Price: £0.39

Market: LSE
Market Cap: £88.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read